Traders should monitor for any near-term share sales under this shelf, particularly through the ATM program, which could pressure the stock. Given the high dilution risk relative to market cap, any announcement of funding activity is likely to be negatively received by the market.
Price Chart
Executive Summary
Kyverna Therapeutics' S-3 shelf registration has become effective, allowing the company to raise up to $300 million through various offerings, including a $100 million ATM with Jefferies. This creates a potential overhang of significant dilution for existing shareholders given the current $536 million market cap.
Key Facts
- S-3 shelf registration effective as of April 2, 2026, permitting Kyverna to raise up to $300 million in capital.
- Up to $100 million may be raised via an ATM offering with Jefferies.
- Proceeds will fund general corporate purposes, including R&D for miv-cel, a CAR-T therapy in development for autoimmune diseases.
- Current market cap is $536 million, meaning the offering could dilute existing shareholders by up to 56% if fully utilized.
- No securities have been issued yet; the effectiveness allows for offerings to occur at management's discretion.
Financial Impact
Up to $300 million in potential dilution, representing approximately 56% of current market cap.
Risk Factors
- Significant equity dilution if the company draws down on the shelf, especially through the ATM.
- Downward pressure on share price if offerings are priced at a discount or executed in weak market conditions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001072 |
| Document: 9999999995-26-001072-index.html | 9999999995-26-001072 |
| Document: 9999999995-26-001072.txt | 9999999995-26-001072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers